卡维地洛治疗扩张型心肌病心力衰竭患者的疗效

目的：观察卡维地洛治疗扩张型心肌病心力衰竭患者的临床疗效。方法：选择扩张型心肌病心力衰竭患者82例，采用随机分组的方法分为卡维地洛组（42例）和常规治疗组（40例），卡维地洛组在常规治疗基础上加用卡维地洛3．125～25mg2次／d。比较两组左室舒张期末内径（LVEDd）、左室收缩期末内径（LVEsd）、左房内径（LAD）、左室射血分数（LVEF）、6min步行距离（6MWD）等指标变化情况。结果：治疗6个月后，两组患者心功能均有改善，卡维地洛组总有效率显著高于常规治疗组（90．5％比72．5％，P〈0．05）；两组治疗后患者的LVEDd、LVESd、LVEF及6MWD均有显著改善（P〈0．05），且与常规治疗组比较，卡维地洛组治疗后患者的LVEDd[（59．1±9．6）mm比（54．2±10．2）mm]、LVESd[（46．1±8．7）mm比（41．4±12．2）mm]显著缩小，LVEF[（42．1±10．5）％比（48．4±9．6）％]及6MWD[（264．52±51．23）m比（309．26±45．24）m]显著增加（P均〈0．05）。结论：在常规治疗基础上加用卡维地洛可明显改善扩张型心肌病心力衰竭患者的疗效。

Therapeutic effect of carvedilol on patients with dilated cardiomyopathy and heart failure

Objective： To observe therapeutic effect of carvedilol on patients with dilated cardiomyopathy （DCM） and heart failure （HF）. Methods： A total of 82 cases with DCM and HF were selected. They were randomly divided into carvedilol group （n = 42） and routine treatment group （n = 40）. Patients in carvedilol group received carvedilol 3. 125-25 mg twice/d based on routine treatment. Changes of left ventricular end-diastolic dimension （LVEDd）, left ventricular end-systolic dimension （LVESd）, left atrial diameter （LAD）, left ventricular ejection fraction （LVEF）, 6 min walking distance （6MWD） were compared between two groups. Results： After six-month treat-ment, there was significant improvement in cardiac function in both groups, and total effective rate of carvedilol group （90.5%） was significantly higher than that of routine treatment group （72.5%）, P〈0.05; Compared with routine treatment group, there were significant decrease in LVEDd [ （59.1 ± 9.6） mm vs. （54.2 ± 10.2） mm], LVESd [ （46.1 ± 8.7） mm vs. （41.4± 12.2） mm] and significant increase in LVEF [ （42.1± 10.5）% vs. （48.4 ± 9.6） %] and 6 MWD [ （264.52 ± 51.23） m vs. （309.26 ± 45.24） m] in carvedilol group, P〈0.05 all. Conclu-sion： Application of carvedilol based on routine treatment can significantly improve therapeutic effect of patients with dilated cardiomyopathy and heart failure.